SIPONIMOD

/static/temp/default.svg

Search structure


Synonyms	BAF-312 BAF312 Baf312 NVP-BAF312-NX Siponimod
Status
Molecule Category	UNKNOWN
ATC	L04AA42
UNII	RR6P8L282I
EPA CompTox	DTXSID40153847


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	KIHYPELVXPAIDH-HNSNBQBZSA-N
Smiles	CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1
InChI	InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C29H35F3N2O3
Molecular Weight	516.6
AlogP	6.77
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	9.0
Polar Surface Area	62.13
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	37.0

Bioactivity

Mechanism of Action	Action	Reference
Sphingosine 1-phosphate receptor Edg-1 agonist	AGONIST	PubMed PubMed FDA


Protein: Sphingosine 1-phosphate receptor Edg-1 Description: Sphingosine 1-phosphate receptor 1 Organism : Homo sapiens P21453 ENSG00000170989

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Lipid-like ligand receptor (family A GPCR) EDG receptor	0	-	-	-	-

Assay Description	Organism	Bioactivity	Reference
Inhibition of human ERG channel at 25 uM	Homo sapiens	10.0 %
Agonist activity at human S1P1 receptor transfected in CHO cells incubated for 10 to 15 mins prior to GTPgamma35S addition measured after 120 mins by GTPgamma35S binding assay	Homo sapiens	0.4 nM
Agonist activity at human S1P5 receptor expressed in CHO cells by [35S]GTPgammaS binding assay	Homo sapiens	0.98 nM
Agonist activity at human S1P4 receptor expressed in CHO cells by [35S]GTPgammaS binding assay	Homo sapiens	750.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	19.01 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	16.98 %		SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	2.722 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.19 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.05 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.05 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.19 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2336071
DrugBank	DB12371
DrugCentral	5326
FDA SRS	RR6P8L282I
Guide to Pharmacology	9289
PubChem	44599207
SureChEMBL	SCHEMBL641699
ZINC	ZINC000006717453

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).